Bavarian Nordic data show challenge of hitting a moving target

Top-line Phase III data from Bavarian Nordic (OMX: BAVA) reflect the difficulties of targeting COVID-19, with a constantly mutating viral threat and an equally changeable regulatory landscape.

Results from a Phase III trial of ABNCoV2, the firm’s VLP-based COVID-19 booster vaccine, show non-inferiority with leading option Comirnaty, in terms of the original “Wuhan” strain.

However, the firm said in a statement, “the primary objective, while important, is likely insufficient to support a product approval on its own.”